¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17
±³À°ÀÏÀÚ : 2021-06-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°(½Ç½Ã°£ È­»ó °­ÀÇ)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  
À̸ÞÀÏ : cancer2@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 18 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 90,000¿ø      
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 6¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 3¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 6¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 9¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 4¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 9¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 Room C 08:30~08:50 Transforming therapeutic strategy from advanced to early stage EGFR-mutation positive NSCLC  ±èŹÎ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 08:50~09:10 Recent update of CheckMate 9LA and CheckMate 227 pivotal trials in 1L NSCLC  ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 09:10~09:30 A new 3G EGFR TKI, lazertinib: It  Á¶º´Ã¶(¿¬¼¼ÀÇ´ë) 
È޽Ġ06-17  09:30~09:40 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 09:40~10:20 Vaccines for cancer prevention and treatment  Mary L. (Nora) Disis(University of Washington) 
È޽Ġ06-17  10:20~10:30 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 10:30~10:55 Single-cell epigenomics  Céline Vallot(Institut Curie) 
±³À°½Ã°£ 06-17 Room A 10:55~11:20 Global epigenetic landscape  Anders Lindroth(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room A 11:20~11:45 Epigenetic therapy  Toshikazu Ushijima(National Cancer Center Research Institute) 
±³À°½Ã°£ 06-17 Room A 11:45~12:10 Epigenetic markers in immunotherapy  ÃÖÁ¤±Õ(KAIST) 
±³À°½Ã°£ 06-17 Room B 10:30~10:55 Development of ctDNA assay and future perspective  ¹æµÎÈñ(¿¬¼¼´ë) 
±³À°½Ã°£ 06-17 Room B 10:55~11:20 ctDNA testing methods and data analysis algorithm  ÀÌ¿ìâ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 11:20~11:45 Clinical application of ctDNA in surgical field  ÇÑ¿ø½Ä(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 11:45~12:10 AI based cancer screening and MRD detection using cfDNA-WGS  Á¶ÀºÇØ(³ì½ÊÀÚ Áö³ð) 
±³À°½Ã°£ 06-17 Room C 10:30~10:55 Benefit and risk of surgical treatment of spinal metastasis  Naresh Kumar(National University Hospital) 
±³À°½Ã°£ 06-17 Room C 10:55~11:20 Radiotherapy for spinal metastasis: Benefit and risk or stereotatic radiotherapy for spinal metastasis  ±è¼ö»ê(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 11:20~11:45 RANKL as a therapeutic target for bone metastasis  Kazuo Okamoto(University of Tokyo) 
±³À°½Ã°£ 06-17 Room C 11:45~12:10 Bone-targeted agents in metastatic bone tumors  ¾ÈÁøÈñ(¿ï»êÀÇ´ë) 
½Ä»ç 06-17  12:10~12:50 ½Ä»ç  () 
±³À°½Ã°£ 06-17 Room A 12:50~13:20 Overview of CDK4/6 inhibitors: From past to future  ÀÌ°æÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 12:50~13:20 Optimal combination therapy with pembrolizumab and TKIs for mRCC  ±èÂù(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 12:50~13:20 Current practice and new approaches with oxaliplatin in GI cancers  ÀüÈ«Àç(Â÷ÀÇ´ë) 
È޽Ġ06-17  13:20~13:30 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 13:30~13:55 Targeting DDR pathways in cancer treatment and selection of the right patients  ÀÓ¼®¾Æ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 13:55~14:20 Clinical evidence of PARP inhibitors: Focusing on breast and ovarian cancer  Á¤°æÇØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 14:20~14:45 DDR in immunotherapy and radiotherapy  Robert Samstein(Icahn School of Medicine at Mount Sinai) 
±³À°½Ã°£ 06-17 Room A 14:45~15:10 New DDR inhibitors and novel strategies for targeting DDR in cancer  Timothy A. Yap(MD Anderson Cancer Center) 
±³À°½Ã°£ 06-17 Room B 13:30~13:55 Lung cancer surgery  ¹Ú¼º¿ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 13:55~14:20 Breast cancer surgery  ÀÌÁØ¿ì(ÀÌ´ë¸ñµ¿º´¿ø) 
±³À°½Ã°£ 06-17 Room B 14:20~14:45 Gastric cancer surgery  ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room B 14:45~15:10 Melanoma surgery  Sandra L. Wong(Dartmouth-Hitchcock Medical Center) 
±³À°½Ã°£ 06-17 Room C 13:30~13:55 Lessons from NCI-COG Pediatric MATCH trial for pediatric precision medicine  Donald Williams Parsons(Baylor College of Medicine Texas Children) 
±³À°½Ã°£ 06-17 Room C 13:55~14:20 Role of immunotherapy for sarcomas  ¹ÚÁ¤¾Æ(Memorial Sloan-Kettering Cancer Center) 
±³À°½Ã°£ 06-17 Room C 14:20~14:45 Molecular profiling of CNS tumors  ¿øÀç°æ(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-17 Room C 14:45~15:10 Recent advances in CAR-T therapy  °­ÇüÁø(¼­¿ïÀÇ´ë) 
È޽Ġ06-17  15:10~15:20 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 15:20~15:45 Proteogenomic landscape of lung adenocarcinoma and its therapeutic targets  Michael A. Gillette(Broad Institute of MIT and Harvard) 
±³À°½Ã°£ 06-17 Room A 15:45~16:10 Proteogenomic characterization of gastric cancer  È²´ëÈñ(¼­¿ï´ë) 
±³À°½Ã°£ 06-17 Room A 16:10~16:35 Proteogenomic landscape of clear cell renal cell carcinoma  Hui Zhang(Johns Hopkins University) 
±³À°½Ã°£ 06-17 Room A 16:35~17:00 Pharmaco-proteogenomics of glioblastoma  ±èÇö¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 15:20~15:45 Hypofractionated RT for breast cancer: From months to a week  ±èÁØ¿ø(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 06-17 Room B 15:45~16:10 Optimized fractionation scheme of radiation therapy for hepatobiliary and pancreatic cancer  ÁöÀDZÔ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 16:10~16:35 SBRT and hypofractionated RT for early stage lung cancer  ³ëÀç¸í(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 16:35~17:00 Pros and cons of hypofractionated RT to bone and brain metastasis  ±è±Ôº¸(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 15:20~15:45 Investigation on improving bioinformatic markers of cancer immunotherapy response by radio-chemotherapy  ±è½Å(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 15:45~16:10 Multidisciplinary approach in young women with breast cancer  ±èÈñÁ¤(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 16:10~16:35 Heterogeneity in tumor-infiltrating lymphocytes: Individualized strategy according to the tumor specificity  ÀÓ°¡¶÷(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 16:35~17:00 Scientific validation and clinical application of lung cancer organoid  Á¤Àç¿í(Ãæ³²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ(OCT angiography in glaucoma) : 2021-06-18
´ÙÀ½±Û 150ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2021-06-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20730 °­¿ø 2024³â °³¿øÀǸ¦ À§ÇÑ ³»°úÇÐ ¿¬¼ö°­Á : 2024-06-02 0 3 2024-05-27
20729 Ãæ³² Á¦16Â÷ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­ ±³À° (»ó¹Ý±â_3ÀÏÂ÷) : 2024-06-02 0 2 2024-05-27
20728 ¼­¿ï 2024³â ´ëÇÑÀÇÇз¹ÀÌÀúÇÐȸ Á¦13Â÷ ¿¬¼ö±³À° : 2024-06-02 0 8 2024-05-27
20727 ¼­¿ï Á¦9ȸ °¡Á¤ÀÇ, È£½ºÇǽº ¿ÏÈ­ÀÇ·á Àü¹®°¡µÇ±â : 2024-06-01 0 5 2024-05-27
20726 ¼­¿ï ÀÌ´ë¼­¿ïº´¿ø »êºÎÀΰú Áö¿ªÀÇ»ç °£´ãȸ(Àӽżº °íÇ÷¾Ð ÁúȯÀÇ Á¶±â ¿¹Ãø°ú ¿¹¹æ) : 2024-06-01 0 2 2024-05-27
20725 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥(ÀÚ±â¾ÖÀû ÀΰÝÀå¾Ö) : 2024-06-01 0 1 2024-05-27
20724 ¼­¿ï °Ç±¹´ëÇб³º´¿ø ´ëÇÑÀÇÁø±ÕÇÐȸ Á¦30Â÷ Çмú´ëȸ : 2024-06-01 0 4 2024-05-27
20723 ¼­¿ï Á¦54Â÷ ´ëÇѼҾƽŰæ¹ß´ÞÇൿ¿¬±¸È¸ ÇмúÁý´ãȸ : 2024-06-01 0 2 2024-05-27
20722 °æ³² Á¦25ȸ °æ³²ÀÇ»çÀÇ ³¯ ±â³ä Á¾ÇÕÇмú´ëȸ[¿Â.¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ] : 2024-06-01 0 7 2024-05-27
20721 ÀüºÏ 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ÀüºÏÁöȸ Á¦12ȸ ¿¬¼ö°­Á : 2024-06-01 0 9 2024-05-27
20720 ¼­¿ï 2023³â Á¦7Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-01 0 32 2024-05-26
20719 ºÎ»ê Á¦516Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³²Áöȸ Çмú´ëȸ : 2024-06-01 0 38 2024-05-26
20718 °æ±â Àü¹®½ÉÀå¼Ò»ý¼ú(ACLS Provider) ½Ã¹Ä·¹À̼Ç(2day) : 2024-06-01 0 26 2024-05-26
20717 Ãæ³² Á¦16Â÷ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­ ±³À° (»ó¹Ý±â_2ÀÏÂ÷) : 2024-06-01 0 25 2024-05-26
20716 ¼­¿ï 2024 ´ëÇѵΰæºÎ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-01 0 15 2024-05-26
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷